论文部分内容阅读
目的:比较乳腺癌细胞经过表柔比星处理前后的生物学行为,探讨表柔比星化疗对乳腺癌转移潜能的影响及机制。方法:人乳腺癌细胞MCF-7和MDA-MB-231分别给予正常培养和表柔比星6小时处理,通过划痕实验和transwell实验比较两组细胞迁移和侵袭能力的差别。MCF-7细胞经过表柔比星处理不同时间后,通过real-time PCR分析细胞中转移相关蛋白1(Metastasis Associated Protein 1,MTA1)表达水平的变化。建立小鼠4T1乳腺癌模型,观察表柔比星化疗对小鼠肺表面乳腺癌转移灶的数量的影响。结果:划痕实验中,处理组MCF-7和MDA-MB-231细胞24小时内平均划痕愈合距离均显著长于对照组细胞(P<0.05);transwell实验中,处理组MDA-MB-231细胞24小时内穿膜细胞数显著多于对照组细胞(P<0.01),MCF-7细胞本身侵袭性低难以穿膜;real-time PCR结果显示,表柔比星处理使MCF-7细胞中MTA1转录水平出现显著上调(P<0.05);动物实验结果显示,处理组小鼠肺表面转移灶数量显著多于对照组(P<0.01)。结论:表柔比星处理可以在体内和体外增强乳腺癌细胞的转移潜能,这一改变可能与其诱导MTA1的表达有关。
OBJECTIVE: To compare the biological behavior of breast cancer cells before and after epirubicin treatment to investigate the effect of epirubicin chemotherapy on metastatic potential of breast cancer and its mechanism. Methods: Human breast cancer cells MCF-7 and MDA-MB-231 were respectively cultured in normal culture and epirubicin for 6 hours. The differences of cell migration and invasion between the two groups were compared by scratch test and transwell assay. MCF-7 cells were treated with epirubicin for different time, and the expression of Metastasis Associated Protein 1 (MTA1) was analyzed by real-time PCR. Mouse model of 4T1 breast cancer was established to observe the effect of epirubicin chemotherapy on the number of metastatic breast cancer on the surface of lung in mice. RESULTS: In the scratch test, the average scratch healing distance in MCF-7 and MDA-MB-231 cells was significantly longer than that in the control group (P <0.05). In the transwell experiment, the MDA-MB- The number of transmembrane cells in 24 hours was significantly higher than that in control cells (P <0.01). The invasiveness of MCF-7 cells was low and it was difficult to penetrate the membrane. The real-time PCR results showed that epirubicin treatment significantly increased the number of MCF-7 cells The level of MTA1 transcription was significantly up-regulated (P <0.05). The results of animal experiments showed that the number of lung surface metastases in the treated group was significantly more than that in the control group (P <0.01). Conclusion: Epirubicin treatment can enhance the metastatic potential of breast cancer cells in vivo and in vitro, and this change may be related to its induction of MTA1 expression.